Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 155Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Leukemia, Myelomonocytic, Acute 31Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 27Leukemia, Megakaryoblastic, Acute 25Congenital Abnormalities 23Burkitt Lymphoma 19Myelodysplastic Syndromes 17Lymphoma 17Leukemia, Biphenotypic, Acute 14Anemia, Refractory, with Excess of Blasts 11Myeloproliferative Disorders 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Eosinophilic, Acute 8Leukemia, Basophilic, Acute 8Neoplasm, Residual 7Leukemia, Promyelocytic, Acute 7Leukemia, Myelomonocytic, Chronic 7Recurrence 6Dendritic Cell Sarcoma, Interdigitating 5Hematologic Neoplasms 4Thrombocytopenia 3Neutropenia 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Non-Hodgkin 3Down Syndrome 3Thrombocythemia, Essential 2

Interventions

thymoglobulin 1selinexor 1fludarabine 1Rituximab 1Reverse Transcriptase Polymerase Chain Reaction 1Panobinostat 1Melphalan 1Levetiracetam 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bronchoalveolar Lavage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome Aberrations × Daunorubicin × Clear all
NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡